Can I Take Melatonin with Dayvigo (Lemborexant)?

How Dayvigo and Melatonin Work on Different Sleep Circuits

Dayvigo and melatonin both promote sleep, but they act through entirely separate receptor systems. Understanding the distinction matters because it explains why stacking the two may produce unpredictable sedation rather than simply "more" of the same effect.

Lemborexant: Blocking the Wake Signal

Lemborexant is a dual orexin receptor antagonist. Orexin-A and orexin-B are neuropeptides produced in the lateral hypothalamus that sustain wakefulness and arousal 1. By competitively binding OX1R and OX2R, lemborexant reduces the excitatory drive that keeps you awake. The drug does not force sleep the way older sedative-hypnotics do. Instead, it removes a barrier to sleep onset and maintenance.

In the SUNRISE-2 trial (N=949), lemborexant 5 mg and 10 mg both reduced subjective wake-after-sleep-onset (sWASO) by roughly 20 to 30 minutes compared to placebo over 12 months of treatment 2. The effect was durable, with no evidence of tolerance or rebound insomnia upon discontinuation.

Melatonin: Shifting the Clock

Melatonin is an endogenous hormone secreted by the pineal gland in response to darkness. Exogenous melatonin at physiologic doses (0.5 to 1 mg) acts primarily as a chronobiotic, shifting circadian phase rather than directly sedating. At higher doses (3 to 10 mg), melatonin does produce mild sedation through MT1-mediated inhibition of the suprachiasmatic nucleus (SCN) 3. A 2013 Cochrane review of 19 trials (N=1,683) found that melatonin reduced sleep-onset latency by a mean of 7.06 minutes compared to placebo 4.

The sleep-onset benefit is modest compared to what prescription agents deliver, which raises the question: if someone is already on Dayvigo, does adding melatonin provide enough incremental benefit to justify the risk?

Why Two Different Mechanisms Can Still Clash

Because lemborexant suppresses wakefulness and melatonin facilitates the circadian transition to sleep, combining them creates two simultaneous pro-sleep signals via distinct neural circuits. The American Academy of Sleep Medicine (AASM) clinical practice guideline (2017) noted that combining sedating agents without clear clinical rationale increases the probability of adverse events without proportionally improving efficacy 5. The FDA's prescribing information for Dayvigo explicitly warns: "Dosage modifications are recommended when DAYVIGO is administered with other CNS depressants" 6.

Is the Interaction Pharmacokinetic or Pharmacodynamic?

This is a pharmacodynamic interaction. That means the drugs do not meaningfully compete for liver enzymes or alter each other's blood levels. The concern is additive downstream effects on brain function.

Liver Metabolism: Minimal Overlap

Lemborexant is metabolized primarily by CYP3A4, with minor contributions from CYP3A5 6. Melatonin is metabolized primarily by CYP1A2, with a secondary pathway through CYP2C19 7. These pathways do not overlap significantly. A pharmacokinetic interaction, where one drug raises or lowers blood levels of the other, is unlikely at standard doses.

This is reassuring from a metabolism standpoint, but it also means that typical "drug interaction checkers" may label this combination as low-risk based on the absence of pharmacokinetic conflict. That label misses the real concern.

The Real Problem: Stacking Sedation

The pharmacodynamic interaction is the clinically relevant one. Both agents reduce arousal through different pathways, and their sedative effects are additive. In a pooled safety analysis of the SUNRISE-1 and SUNRISE-2 trials (N=1,982), somnolence occurred in 10% of patients on lemborexant 10 mg versus 1% on placebo 2. Adding any additional sedating substance on top of that baseline somnolence risk compounds the problem.

Dr. Andrew Krystal, a principal investigator in the SUNRISE trials and professor of psychiatry at UC San Francisco, has stated: "Orexin antagonists have a distinct safety advantage over older hypnotics, but that advantage erodes when patients layer additional sedating agents on top, whether those are prescription drugs, alcohol, or supplements like melatonin" 8.

What Happens If You Take Both Together?

The risks of combining Dayvigo with melatonin fall into three categories: next-morning impairment, complex sleep behaviors, and metabolic effects.

Next-Morning Drowsiness and Driving Safety

Lemborexant has a half-life of approximately 17 to 19 hours 6. Melatonin's half-life is shorter (40 to 60 minutes for immediate-release formulations), but extended-release products can maintain elevated levels for 6 to 8 hours. Taking both at bedtime means peak sedation from melatonin coincides with the early absorption phase of lemborexant. Even after melatonin wears off, lemborexant's prolonged duration may leave residual impairment that was deepened by the initial melatonin dose.

The FDA's Dayvigo label includes a specific warning about driving impairment, noting that next-day driving ability may be impaired even after a full night of sleep 6. Layering melatonin compounds this risk. No controlled study has measured driving performance in patients taking both agents together.

Complex Sleep Behaviors

The Dayvigo label carries a boxed-style warning for complex sleep behaviors, including sleepwalking, sleep-driving, and engaging in activities while not fully awake 6. These events are rare in clinical trial populations. They are more common in the presence of other CNS-active substances. Melatonin at supraphysiologic doses (5 mg or more) has been independently associated with vivid dreams and parasomnias in case reports 9.

Effects on Glucose Metabolism

Melatonin influences glucose tolerance through MT2 receptor activation in pancreatic beta cells. A 2020 study published in Cell Metabolism (N=17,000 genotyped participants) found that a common MTNR1B variant amplifies melatonin's glucose-raising effect, increasing 2-hour glucose by approximately 0.3 mmol/L after evening melatonin administration 10. Lemborexant itself carries no significant glycemic signal. For patients with prediabetes or type 2 diabetes already on Dayvigo, adding high-dose melatonin could introduce an unnecessary metabolic variable.

Dose-Separation Strategies and Practical Guidance

If your physician determines that both agents are necessary (for example, melatonin for jet lag and Dayvigo for chronic insomnia), dose separation and dose minimization can reduce risk.

Timing Matters

Melatonin for circadian phase-shifting is most effective when taken 2 to 4 hours before desired bedtime at a dose of 0.5 to 1 mg 3. Dayvigo should be taken within 30 minutes of bedtime. This creates a natural separation window. Taking low-dose melatonin at 7:00 PM and Dayvigo at 10:30 PM, for example, means melatonin's sedative peak has already passed before lemborexant reaches full effect.

Keep Melatonin Doses Physiologic

Most over-the-counter melatonin products contain 3 to 10 mg per tablet. That is 3 to 20 times the physiologic dose. A 2022 JAMA study tested 25 commercial melatonin gummy products and found that actual melatonin content ranged from 74% to 347% of the labeled dose 11. Some products also contained CBD. If combining with Dayvigo, use a pharmaceutical-grade melatonin product at 0.5 mg or less, and verify third-party testing through USP or NSF certification.

Monitoring Checklist

When your prescriber approves concurrent use, watch for these signals during the first two weeks:

• Morning grogginess lasting more than 60 minutes after waking
• Difficulty with coordination, balance, or reaction time
• Reports from a bed partner of unusual nighttime behavior
• Changes in fasting blood glucose (particularly relevant for patients with MTNR1B risk variants or existing dysglycemia)
• Mood changes, including worsening depression or suicidal ideation (a rare but labeled risk for all DORAs)

Report any of these to your provider. Do not adjust doses independently.

Who Should Avoid This Combination Entirely?

Certain populations face higher risk from combining Dayvigo and melatonin.

Older Adults

Adults over 65 already experience higher lemborexant exposure due to reduced hepatic clearance. In the SUNRISE-1 trial, elderly patients (mean age 71.3) on lemborexant 5 mg showed a somnolence rate of 8.4% 1. Adding melatonin to an already-elevated drug exposure raises fall risk significantly. The American Geriatrics Society Beers Criteria recommend avoiding combinations of sedating agents in patients 65 and older 12.

Patients on CYP3A4 Inhibitors

While melatonin does not inhibit CYP3A4, patients already taking moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem) are on a reduced Dayvigo dose of 5 mg per the FDA label 6. These patients already have elevated lemborexant levels. Piling melatonin onto that elevated baseline intensifies pharmacodynamic risk without pharmacokinetic explanation, making the interaction harder to predict and manage.

Patients with Narcolepsy or Hypersomnia

Dayvigo is contraindicated in narcolepsy. Patients with a history of hypersomnolence disorders should not combine any orexin antagonist with additional sedating agents 5.

What If You Are Already Taking Both?

Do not stop either medication abruptly without medical guidance. Here is a practical path forward.

Step 1: Document Your Current Regimen

Write down the exact melatonin product name, labeled dose, time of administration, and how long you have been taking it. Bring the bottle to your next appointment so your provider can verify the formulation.

Step 2: Discuss Tapering Melatonin First

Because melatonin is the supplement (not the prescription agent targeted at your diagnosed insomnia), it is usually the appropriate agent to taper. Most patients can reduce melatonin by 50% every 3 to 5 days without rebound effects, given melatonin's low dependence potential 4.

Step 3: Reassess Sleep Quality on Dayvigo Alone

After a 2-week washout from melatonin, use a sleep diary or validated tool like the Insomnia Severity Index (ISI) to measure whether Dayvigo alone maintains adequate sleep. In the SUNRISE-2 trial, 73.9% of patients on lemborexant 5 mg rated their condition as "much improved" or "very much improved" on the Patient Global Impression of Change (PGI-C) at 6 months without additional sleep aids 2.

Step 4: Consider Cognitive Behavioral Therapy for Insomnia (CBT-I)

The AASM and the American College of Physicians both recommend CBT-I as first-line treatment for chronic insomnia 13. A 2015 meta-analysis in Annals of Internal Medicine (N=1,162) found that CBT-I improved sleep-onset latency by 19.03 minutes and WASO by 26.00 minutes, effects comparable to pharmacotherapy but without medication side effects 13. If you are reaching for melatonin because Dayvigo alone is insufficient, CBT-I is a safer adjunct than a second sedating agent.

How This Compares to Other Supplement-Dayvigo Combinations

Melatonin is not the only supplement that patients ask about combining with Dayvigo. The same pharmacodynamic caution applies to valerian root, magnesium glycinate (at sedating doses above 400 mg), L-theanine, and CBD.

Among these, melatonin carries a unique additional concern: the glucose-metabolism signal linked to MTNR1B variants 10. CBD adds a pharmacokinetic layer because cannabidiol inhibits CYP3A4, potentially raising lemborexant levels 6. Magnesium and L-theanine have milder sedative profiles and fewer documented interactions, though controlled data with DORAs specifically are absent.

The Endocrine Society's 2015 clinical practice guideline on melatonin cautioned: "The widespread availability of melatonin as a dietary supplement has outpaced the evidence base for its long-term safety, particularly in combination with prescription sleep aids" 14.

The Bottom Line on Dayvigo and Melatonin

The interaction is pharmacodynamic, not pharmacokinetic. Liver-enzyme competition is minimal, but additive sedation through two distinct neural pathways creates real clinical risk: morning impairment, falls (particularly in older adults), complex sleep behaviors, and potential glucose disruption in genetically susceptible individuals. If both agents are temporarily necessary, keep melatonin at 0.5 mg or less, separate dosing by at least 3 hours, and plan to taper the supplement within 2 to 4 weeks under prescriber supervision.